---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074163"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:22:10.185571+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rigel Q2 net income $59.6M, revenue $101.7M; raises FY2025 guidance to $270-280M

## Summary
- Q2 2025 total revenue $101.7M (net product sales $58.9M, up 76% YoY); net income $59.6M vs loss $1.0M in Q2 2024.
- Raised FY2025 guidance: total revenue $270-280M (prev $200-210M); net product sales $210-220M (prev $185-192M).
- Cash and investments increased to $108.4M from $77.3M at Dec 31, 2024.
- TAVALISSE sales $40.1M (+52% YoY), GAVRETO $11.8M, REZLIDHIA $7.0M (+36%).
- Completed enrollment in dose escalation part of Phase 1b study for R289 in R/R lower-risk MDS; dose expansion later this year.

## SEC filing metadata
- accession: 0001104659-25-074163
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/0001104659-25-074163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/tm2522417d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074163
- JSON: https://secwatch.observer/filing/0001104659-25-074163.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.